246 related articles for article (PubMed ID: 20094025)
21. Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Feb; 59(5):130-2. PubMed ID: 20150888
[TBL] [Abstract][Full Text] [Related]
22. An outbreak of yellow fever with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005.
Gould LH; Osman MS; Farnon EC; Griffith KS; Godsey MS; Karch S; Mulenda B; El Kholy A; Grandesso F; de Radiguès X; Brair ME; Briand S; El Tayeb el SM; Hayes EB; Zeller H; Perea W
Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1247-54. PubMed ID: 18502458
[TBL] [Abstract][Full Text] [Related]
23. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
26. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
[TBL] [Abstract][Full Text] [Related]
27. Viscerotropic disease following yellow fever vaccination in Peru.
Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
[TBL] [Abstract][Full Text] [Related]
28. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
29. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
30. [Yellow fever].
Wiercińska-Drapało A
Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
[TBL] [Abstract][Full Text] [Related]
31. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy.
Roukens AH; Vossen AC; van Dissel JT; Visser LG
Vaccine; 2009 Apr; 27(18):2408-9. PubMed ID: 19368780
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.
Hepburn MJ; Kortepeter MG; Pittman PR; Boudreau EF; Mangiafico JA; Buck PA; Norris SL; Anderson EL
Vaccine; 2006 Apr; 24(15):2843-9. PubMed ID: 16494976
[TBL] [Abstract][Full Text] [Related]
33. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
[TBL] [Abstract][Full Text] [Related]
34. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
[TBL] [Abstract][Full Text] [Related]
35. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
[TBL] [Abstract][Full Text] [Related]
36. Yellow fever - prevention in travellers.
Neilson AA; Mayer CA
Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.
Sidibe M; Yactayo S; Kalle A; Sall AA; Sow S; Ndoutabe M; Perea W; Avokey F; Lewis RF; Veit O
Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):437-44. PubMed ID: 22627101
[TBL] [Abstract][Full Text] [Related]
38. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
39. Suspected YF-AND after yellow fever vaccination in Finland.
Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
[TBL] [Abstract][Full Text] [Related]
40. Duration of seropositivity following yellow fever vaccination in U.S. military service members.
Lindsey NP; Perry L; Fischer M; Woolpert T; Biggerstaff BJ; Brice G; Fitzpatrick K; Kosoy OI; Laven JJ; Myers CA; Hollis EM; Staples JE
Vaccine; 2020 Dec; 38(52):8286-8291. PubMed ID: 33239225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
